Title Biological disease modifying drugs in treatment of crystal-induced arthritis
Translation of Title Biological Disease Modifying Drugs in Treatment of Crystal-Induced Arthritis.
Authors Hake, Julie
Full Text Download
Pages 48
Keywords [eng] Crystal arthropathies, Gout, Calcium pyrophosphate deposition disease, Basic calcium phosphate deposition disease, EULAR (European Alliance of Associations for Rheumatology), ACR (American College of Rheumatology), Biological disease-modifying drugs
Abstract [eng] Crystal-induced arthropathies stands for a group of inflammatory joint disorders, which involve microcrystal deposition that causes recurrent episodes and sometimes chronic inflammation. Conventional anti-inflammatory therapies are effective in many cases, however numerous patients experience insufficient response or contraindications, especially in the setting of advanced age and comorbidities. Progress in the understanding of the innate immune system´s part in these diseases have drawn attention to cytokine-driven pathways as potential therapeutic targets. The aim of this literature review is to review available evidence on the use of biological disease-modifying drugs in the treatment of crystal-induced arthropathies. This literature review assesses the role of interleukin-1-dependent inflammatory pathways in crystal arthropathies and synthesizes available clinical data on biological therapies used for this context. The efficacy and safety profiles of interleukin-1 inhibitors, namely anakinra, rilonacept and canakinumab, are assessed based on published clinical studies. Additionally, current limitations in the clinical evidence are identified and subjects that need further research are stressed. The reviewed literature implies that biologic therapies may offer effective treatment alternatives for certain patient groups with refractory disease or contraindications to standard treatment. Nevertheless, limited high quality clinical data restrict definitive conclusions at this point of time. More deliberate clinical trials are essential to further define the role of biological disease-modifying drugs in the treatment of crystal-induced arthropathies.
Dissertation Institution Vilniaus universitetas.
Type Master thesis
Language English
Publication date 2026